Genmab stock reportedly rose 60% in October on cancer treatment 'hat trick'
Investor's Business Daily reported that Genmab stock skyrocketed 60% over the course of October, attributing the move to an unexpected "hat trick" in cancer treatment according to its CEO. The post does not specify the individual components of the hat trick or any further figures beyond the 60% monthly gain.
Why “Unverified”
- Reported by Investor's Business Daily alone, with no second source or primary confirmation yet
1 independent source group across 1 post · evidence score 52/100. How labels work
What the sources claim
-
Genmab stock rose 60% over October, according to the report.
“Genmab stock skyrocketed 60% over the course of October”
Investor's Business Daily -
Genmab's CEO attributed the move to an unexpected "hat trick" in cancer treatment.
“on an unexpected "hat trick" in cancer treatment, according to its CEO”
Investor's Business Daily
Sources
More in Stocks & Indices
Embed this page
Summary and claims extracted by AI with prompt analyze-story@5 on 2026-11-20 13:10 UTC. Labels are computed from the sources, not by the model.